EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early consequences of the phospholamban mutation PLN‐R14del +/− in a transgenic mouse model

Claudia Maniezzi, Marem Eskandr, Chiara Florindi, Mara Ferrandi, Paolo Barassi, Elena Sacco iD, Valentina Pasquale, Angela S Maione, Giulio Pompilio, Vivian Oliveira Nunes Teixeira, Rudolf A de Boer, Herman H W Silljé und 2 weitere

Acta Physiologica · 2024-03 · 240 (3)

DOI: 10.1111/apha.14082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Physiologica, online erschienen am 12.01.2024. Verfasst von Claudia Maniezzi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Bioscience, University of Milano-Bicocca, Milan, Italy. Hauptthemen laut MEDLINE: Cardiomyopathies. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Generation of the PLN-R14del murine model was supported by grants from the Netherlands Heart Foundation (CVON PREDICT2, Grant/award: 2018-30, CVON DOUBLE DOSE, Grant/award, 2020B005 and CarMa, Grant/award:01-003-2022-0358)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The heterozygous phospholamban (PLN) mutation R14del (PLN R14del +/− ) is associated with a severe arrhythmogenic cardiomyopathy (ACM) developing in the adult. “Superinhibition” of SERCA2a by PLN R14del is widely assumed to underlie the pathogenesis, but alternative mechanisms such abnormal energy metabolism have also been reported. This work aims to (1) to evaluate Ca 2+ dynamics and energy metabolism in a transgenic (TG) mouse model of the mutation prior to cardiomyopathy development; (2) to test whether they are causally connected.

Methods

Ca 2+ dynamics, energy metabolism parameters, reporters of mitochondrial integrity, energy, and redox homeostasis were measured in ventricular myocytes of 8–12 weeks‐old, phenotypically silent, TG mice. Mutation effects were compared to pharmacological PLN antagonism and analyzed during modulation of sarcoplasmic reticulum (SR) and cytosolic Ca 2+ compartments. Transcripts and proteins of relevant signaling pathways were evaluated.

Results

The mutation was characterized by hyperdynamic Ca 2+ handling, compatible with a loss of SERCA2a inhibition by PLN. All components of energy metabolism were depressed; myocyte energy charge was preserved under quiescence but reduced during stimulation. Cytosolic Ca 2+ buffering or SERCA2a blockade reduced O 2 consumption with larger effect in the mutant. Signaling changes suggest cellular adaptation to perturbed Ca 2+ dynamics and response to stress.

Conclusions

(1) PLN R14del +/− loses its ability to inhibit SERCA2a, which argues against SERCA2a superinhibition as a pathogenetic mechanism; (2) depressed energy metabolism, its enhanced dependency on Ca 2+ and activation of signaling responses point to an early involvement of metabolic stress in the pathogenesis of this ACM model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomyopathiesAnimalsMiceCalciumCalcium-Binding ProteinsMice, TransgenicMutationMyocytes, CardiacSarcoplasmic Reticulum Calcium-Transporting ATPasesPhospholamban

Stichwörter der Autor:innen

PLN R14del+/−PLN-SERCA2a interactionarrhythmogenic cardiomyopathyenergy metabolismphospholamban

Substanzen

CalciumCalcium-Binding ProteinsSarcoplasmic Reticulum Calcium-Transporting ATPasesPhospholambanAtp2a2 protein, mouse

Autor:innen und Institutionen

  • Department of Biotechnology and Bioscience, University of Milano-Bicocca, Milan, Italy.
  • Windtree Therapeutics Inc., Warrington, Pennsylvania, USA.
  • Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino IRCCS, Milan, Italy.
  • Department of Biomedical, Surgical and Dentist Sciences, University of Milano, Milan, Italy.
  • Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
  • Department of Cardiology, Erasmus University Medical Center, University of Rotterdam, Rotterdam, Netherlands.

ORCID-Profile: Elena Sacco, Francesco Lodola

Förderung

  • Generation of the PLN-R14del murine model was supported by grants from the Netherlands Heart Foundation (CVON PREDICT2, Grant/award: 2018-30
  • CVON DOUBLE DOSE, Grant/award
  • 2020B005 and CarMa, Grant/award:01-003-2022-0358).

Zitieren

APA

Maniezzi, C., Eskandr, M., Florindi, C., Ferrandi, M., Barassi, P., Sacco, E., Pasquale, V., Maione, A. S., Pompilio, G., Teixeira, V. O. N., de Boer, R. A., Silljé, H. H. W., Lodola, F., & Zaza, A. (2024). Early consequences of the phospholamban mutation PLN‐R14del +/− in a transgenic mouse model. Acta Physiologica, 240(3). https://doi.org/10.1111/apha.14082

Vancouver

Maniezzi C, Eskandr M, Florindi C, Ferrandi M, Barassi P, Sacco E, et al. Early consequences of the phospholamban mutation PLN‐R14del +/− in a transgenic mouse model. Acta Physiologica. 2024;240(3). doi:10.1111/apha.14082

BibTeX
@article{Maniezzi2024,
  author = {Maniezzi, Claudia and Eskandr, Marem and Florindi, Chiara and Ferrandi, Mara and Barassi, Paolo and Sacco, Elena and Pasquale, Valentina and Maione, Angela S and Pompilio, Giulio and Teixeira, Vivian Oliveira Nunes and de Boer, Rudolf A and Silljé, Herman H W and Lodola, Francesco and Zaza, Antonio},
  title = {Early consequences of the phospholamban mutation PLN‐R14del +/− in a transgenic mouse model},
  journal = {Acta Physiologica},
  year = {2024},
  volume = {240},
  number = {3},
  doi = {10.1111/apha.14082}
}
Kostenlos starten →